Quicklinks

Course Overview

Gastrointestinal cancers represent the most prevalent form of malignancy in the U.S. Novel treatments have resulted in considerable improvements in patient outcome, but they also increase the complexity of treatment decisions for practicing physicians. Our annual symposium for medical and radiation oncologists, surgeons, gastroenterologists, primary care physicians, and other interested clinicians is intended to educate practitioners on the state of GI cancer management and prevention.

Through lectures, case-based presentations, review of cases presented by attendees, and Q&A, participants will gain a better understanding of these new advances and treatment strategies, and learn how to integrate this knowledge into routine clinical practice.

Learning Objectives

At the conclusion of this course, attendees will be able to: define new radiation approaches for the management of GI cancer and apply these procedures into routine clinical practice; recognize appropriate management and treatment options for colorectal, pancreatic, hepatocellular, and biliary cancers, and neuroendocrine tumors, and where appropriate, utilize these approaches in routine clinical practice; and define new surgical approaches for the management of gastric cancer and apply these procedures into routine clinical practice

ACGME COMPETENCIES: This course is designed to enhance one or more of the following Accreditation Council of Graduate Medical Education competencies: Patient Care, Medical Knowledge, and Practice-based Learning and Improvement.

About the Gastrointestinal Cancer Centers of Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center

We offer comprehensive care for patients with gastrointestinal cancers, including cancers of the colon, rectum, stomach, esophagus, pancreas, anus, bile duct (cholangiocarcinoma), liver, gallbladder, and small bowel, as well as carcinoid and islet cell malignancies. At each cancer center, care is provided by a multidisciplinary team that includes medical oncologists; radiation oncologists; colorectal, gastrointestinal, and oncologic surgeons; and gastroenterologists, with consultative support from gastrointestinal pathologists and gastrointestinal diagnostic and interventional radiologists.

These Harvard Medical School-affiliated centers provide the latest therapies in surgery, chemotherapy, and radiation for gastrointestinal cancers. Both centers also have active clinical research programs exploring new drug treatments and multimodality therapies. Genetic counseling, molecular diagnostic testing, and support services, including social work, nutrition counseling, and educational and support groups are also offered.

HMS Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

CME Credits

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Harvard Medical School designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.